Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition

abstract: Sensitivity is a fundamental challenge for in vivo molecular magnetic resonance imaging (MRI). Here, I improve the sensitivity of metal nanoparticle contrast agents by strategically incorporating pure and doped metal oxides in the nanoparticle core, forming a soluble, monodisperse, contras...

Full description

Bibliographic Details
Other Authors: Clavijo Jordan, Maria Veronica (Author)
Format: Doctoral Thesis
Language:English
Published: 2012
Subjects:
MRI
Online Access:http://hdl.handle.net/2286/R.I.15999
id ndltd-asu.edu-item-15999
record_format oai_dc
spelling ndltd-asu.edu-item-159992018-06-22T03:03:34Z Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition abstract: Sensitivity is a fundamental challenge for in vivo molecular magnetic resonance imaging (MRI). Here, I improve the sensitivity of metal nanoparticle contrast agents by strategically incorporating pure and doped metal oxides in the nanoparticle core, forming a soluble, monodisperse, contrast agent with adjustable T2 or T1 relaxivity (r2 or r1). I first developed a simplified technique to incorporate iron oxides in apoferritin to form "magnetoferritin" for nM-level detection with T2- and T2* weighting. I then explored whether the crystal could be chemically modified to form a particle with high r1. I first adsorbed Mn2+ ions to metal binding sites in the apoferritin pores. The strategic placement of metal ions near sites of water exchange and within the crystal oxide enhance r1, suggesting a mechanism for increasing relaxivity in porous nanoparticle agents. However, the Mn2+ addition was only possible when the particle was simultaneously filled with an iron oxide, resulting in a particle with a high r1 but also a high r2 and making them undetectable with conventional T1-weighting techniques. To solve this problem and decrease the particle r2 for more sensitive detection, I chemically doped the nanoparticles with tungsten to form a disordered W-Fe oxide composite in the apoferritin core. This configuration formed a particle with a r1 of 4,870mM-1s-1 and r2 of 9,076mM-1s-1. These relaxivities allowed the detection of concentrations ranging from 20nM - 400nM in vivo, both passively injected and targeted to the kidney glomerulus. I further developed an MRI acquisition technique to distinguish particles based on r2/r1, and show that three nanoparticles of similar size can be distinguished in vitro and in vivo with MRI. This work forms the basis for a new, highly flexible inorganic approach to design nanoparticle contrast agents for molecular MRI. Dissertation/Thesis Clavijo Jordan, Maria Veronica (Author) Bennett, Kevin M (Advisor) Kodibagkar, Vikram (Committee member) Sherry, A Dean (Committee member) Wang, Xiao (Committee member) Yarger, Jeffery (Committee member) Arizona State University (Publisher) Biomedical engineering Biophysics Apoferritin Manganese MRI Tungsten eng 144 pages Ph.D. Bioengineering 2012 Doctoral Dissertation http://hdl.handle.net/2286/R.I.15999 http://rightsstatements.org/vocab/InC/1.0/ All Rights Reserved 2012
collection NDLTD
language English
format Doctoral Thesis
sources NDLTD
topic Biomedical engineering
Biophysics
Apoferritin
Manganese
MRI
Tungsten
spellingShingle Biomedical engineering
Biophysics
Apoferritin
Manganese
MRI
Tungsten
Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition
description abstract: Sensitivity is a fundamental challenge for in vivo molecular magnetic resonance imaging (MRI). Here, I improve the sensitivity of metal nanoparticle contrast agents by strategically incorporating pure and doped metal oxides in the nanoparticle core, forming a soluble, monodisperse, contrast agent with adjustable T2 or T1 relaxivity (r2 or r1). I first developed a simplified technique to incorporate iron oxides in apoferritin to form "magnetoferritin" for nM-level detection with T2- and T2* weighting. I then explored whether the crystal could be chemically modified to form a particle with high r1. I first adsorbed Mn2+ ions to metal binding sites in the apoferritin pores. The strategic placement of metal ions near sites of water exchange and within the crystal oxide enhance r1, suggesting a mechanism for increasing relaxivity in porous nanoparticle agents. However, the Mn2+ addition was only possible when the particle was simultaneously filled with an iron oxide, resulting in a particle with a high r1 but also a high r2 and making them undetectable with conventional T1-weighting techniques. To solve this problem and decrease the particle r2 for more sensitive detection, I chemically doped the nanoparticles with tungsten to form a disordered W-Fe oxide composite in the apoferritin core. This configuration formed a particle with a r1 of 4,870mM-1s-1 and r2 of 9,076mM-1s-1. These relaxivities allowed the detection of concentrations ranging from 20nM - 400nM in vivo, both passively injected and targeted to the kidney glomerulus. I further developed an MRI acquisition technique to distinguish particles based on r2/r1, and show that three nanoparticles of similar size can be distinguished in vitro and in vivo with MRI. This work forms the basis for a new, highly flexible inorganic approach to design nanoparticle contrast agents for molecular MRI. === Dissertation/Thesis === Ph.D. Bioengineering 2012
author2 Clavijo Jordan, Maria Veronica (Author)
author_facet Clavijo Jordan, Maria Veronica (Author)
title Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition
title_short Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition
title_full Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition
title_fullStr Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition
title_full_unstemmed Design of Apoferritin-Based Nanoparticle MRI Contrast Agents Through Controlled Metal Deposition
title_sort design of apoferritin-based nanoparticle mri contrast agents through controlled metal deposition
publishDate 2012
url http://hdl.handle.net/2286/R.I.15999
_version_ 1718699935137792000